These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 19878255)

  • 1. The clinical challenges of managing type 2 diabetes and the potential of GLP-1-based therapies.
    Zinman B
    Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():1-3. PubMed ID: 19878255
    [No Abstract]   [Full Text] [Related]  

  • 2. Harnessing the weight-regulating properties of glucagon-like peptide-1 in the treatment of type 2 diabetes.
    Sesti G
    Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():4-10. PubMed ID: 19878256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and emerging therapies: an overview of incretin-based therapy in the management of type 2 diabetes.
    Pratley RE
    J Am Acad Nurse Pract; 2008 Nov; 20 Suppl 1():7-11. PubMed ID: 19402254
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of glucagon-like peptide-1 on endothelial function.
    Sjöholm A
    Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():19-25. PubMed ID: 19878258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incretins: the novel therapy of type 2 diabetes.
    Thongtang N; Sriwijitkamol A
    J Med Assoc Thai; 2008 Jun; 91(6):943-54. PubMed ID: 18697398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin treatment for type 2 diabetes: when to start, which to use.
    Hamaty M
    Cleve Clin J Med; 2011 May; 78(5):332-42. PubMed ID: 21536829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GLP-1 agonists: improving the future of patients with type 2 diabetes.
    Shubrook JH
    J Am Osteopath Assoc; 2011 Feb; 111(2 Suppl 1):2 p preceding eS2. PubMed ID: 21409846
    [No Abstract]   [Full Text] [Related]  

  • 8. [DPP-IV inhibitors and GLP-1 analogues].
    Zettl H; Steinhilber D
    Pharm Unserer Zeit; 2010 Mar; 39(2):108-13. PubMed ID: 20196037
    [No Abstract]   [Full Text] [Related]  

  • 9. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies.
    Chilton R; Wyatt J; Nandish S; Oliveros R; Lujan M
    Am J Med; 2011 Jan; 124(1 Suppl):S35-53. PubMed ID: 21194579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incretins and other peptides in the treatment of diabetes.
    Todd JF; Bloom SR
    Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current challenges in type 2 diabetes.
    Garber AJ
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():1-3. PubMed ID: 22405263
    [No Abstract]   [Full Text] [Related]  

  • 13. Incretin based therapies for type 2 diabetes mellitus.
    Ghosh S; Collier A; Elhadd T; Malik I
    J Indian Med Assoc; 2008 Jun; 106(6):373-4, 383, 388. PubMed ID: 18839649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novo Nordisk replies to BMJ investigation on incretins and pancreatic damage.
    Moses A
    BMJ; 2013 Jul; 347():f4386. PubMed ID: 23842435
    [No Abstract]   [Full Text] [Related]  

  • 15. What's new in diabetes: incretins and C-peptide.
    Marks V
    Med Princ Pract; 2011; 20(2):101-2. PubMed ID: 21252561
    [No Abstract]   [Full Text] [Related]  

  • 16. [Antidiabetics and the incretin system].
    Høibraaten E; Folkersen J
    Tidsskr Nor Laegeforen; 2008 Sep; 128(17):1985. PubMed ID: 18787580
    [No Abstract]   [Full Text] [Related]  

  • 17. Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?
    Olansky L
    Cleve Clin J Med; 2010 Aug; 77(8):503-5. PubMed ID: 20682512
    [No Abstract]   [Full Text] [Related]  

  • 18. Combination therapy with liraglutide and sulfonylurea for a type 2 diabetic patient with high titer of anti-insulin antibodies produced by insulin therapy.
    Yoshida M; Asai M; Miyata M; Ogawa K; Maeda H; Oiso Y
    Diabetes Res Clin Pract; 2012 Jun; 96(3):e55-6. PubMed ID: 22257418
    [No Abstract]   [Full Text] [Related]  

  • 19. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus.
    Triplitt C; Wright A; Chiquette E
    Pharmacotherapy; 2006 Mar; 26(3):360-74. PubMed ID: 16503716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide-1 agonists in the treatment of type 2 diabetes.
    Edwards CM
    Br J Hosp Med (Lond); 2013 Apr; 74(4):198-201. PubMed ID: 23571389
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.